Physician profile
Bryan W Huffman
NPI 1013999853
$2,064.14
in general payments reported to CMS, 2019-2025
21 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $123 · 2021: $242 · 2022: $483 · 2023: $329 · 2024: $149 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $529.03 | 2019-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Kala Pharmaceuticals, INC. | $218.00 | 2019-2021 | |
| Oyster Point Pharma, INC. | $190.04 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $122.51 | 2021-2025 | Cequa |
| Allergan, INC. | $114.64 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $107.69 | 2019-2022 | |
| Biotissue Holdings INC. | $92.86 | 2021-2025 | |
| Aerie Pharmaceuticals, INC. | $90.10 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $85.92 | 2022-2025 | Vyzulta, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $78.90 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $67.24 | 2024-2025 | Xdemvy |
| Abbvie INC. | $66.62 | 2022-2023 | |
| Hoffmann-La Roche Limited | $63.64 | 2019 | |
| Horizon Therapeutics Plc | $45.56 | 2023 | Tepezza |
| Thea Pharma INC. | $41.47 | 2023-2025 | Iyuzeh |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $39.85 | 2019 | |
| Harrow Eye, LLC | $28.46 | 2025 | Vevye |
| Rxsight INC | $24.48 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Dompe US, INC. | $22.59 | 2022 | |
| Amgen INC. | $19.11 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $15.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.